Old Web
English
Sign In
Acemap
>
authorDetail
>
T. J. Ong
T. J. Ong
Medicine
Internal medicine
Pathology
non-small cell lung cancer (NSCLC)
Carboplatin
6
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
3109 nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle
2015
European Journal of Cancer
C. Gridelli
L Li
M. Obrien
T. J. Ong
Robert Pirker
Mark A. Socinski
Michael Thomas
Show All
Source
Cite
Save
Citations (0)
Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).
2011
Journal of Clinical Oncology
George R. Blumenschein
Julian R. Molina
Chetan Lathia
T. J. Ong
D. Roth
Prabhu Rajagopalan
Frank V. Fossella
M. S. Kies
Randolph Stuart Marks
A. A. Adjei
Pavur Sundaresan
Show All
Source
Cite
Save
Citations (1)
A phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumours
2007
Journal of Clinical Oncology
Heather Shaw
L. R. Molife
James Spicer
Vasilios Karavasilis
C. Marriott
T. J. Ong
L. Tate
E. Brendel
O. Christensen
J. de Bono
Show All
Source
Cite
Save
Citations (0)
Nutritional genomics : science, medicine and the future
2002
BMJ
R. Elliott
T. J. Ong
Show All
Source
Cite
Save
Citations (0)
Femoral head measurement in hemiarthroplasty: assessment of interobserver error using 3 measuring systems
2000
Injury-international Journal of The Care of The Injured
J. A. Jeffery
T. J. Ong
Show All
Source
Cite
Save
Citations (12)
1